Double-Blind Randomized Clinical Trial of the Efficacy of Venlafaxine Versus Citalopram in the Treatment of the Acute Phase of Major Depressive Disorder

被引:0
|
作者
Hosseini, Fatemeh [1 ]
Amini, Fariba [1 ]
Ardekani, Seyed [1 ]
Shariat, Neda [1 ]
Nadi, Mohammad [1 ]
机构
[1] Shahid Sadoughi Univ Med Sci, Sch Med, Dept Psychiat, Yazd, Iran
关键词
Citalopram; Depressive Disorder; Venlafaxine;
D O I
10.17795/ijpbs1041
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background: There are many antidepressant medications with different side-effects and efficacy profiles. Objectives: In this study, we compared the efficacy of citalopram and venlafaxine in major depression, which has not yet been studied in Iran. Patients and Methods: In this double-blind, randomized controlled trial study 39 patients aged 18-54 year old with major depressive disorder were randomly allocated into two groups in Yazd City, Iran, between March 2011 and December 2012. A total of 16 patients were treated with velafaxine and 23 patients were treated with citalopram for 8 weeks. Hamilton Depression Rating Scale (HDRS) questionnaire was used for monitoring depression severity. Data were analyzed by SPSS version 20.0 software using Mann Whitney U test and chi-square statistical tests. Results: The HDRS scores were decreased significantly in each group after 8 weeks of treatment (P = 0.001). However, there was no significant difference considering the score of HDRS (P = 0.110). Ten patients in the venlafaxine group and two patients in the citalopram group stopped using medication, all due to nausea or vomiting, or both, and the rate of these two side-effects was significantly higher in the venlafaxine group (P = 0.010). Conclusions: The efficacy of venlafaxine and citalopram are almost the same, but compliance for the use of medication, such as nausea and vomiting, in patients using venlafaxine is much higher than the citalopram group. Therefore, this implies that citalopram could be a safer antidepressant for patients suffering from major depression.
引用
收藏
页码:5 / 9
页数:5
相关论文
共 50 条
  • [31] Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
    Rickels, Karl
    Athanasiou, Maria
    Robinson, Donald S.
    Gibertini, Michael
    Whalen, Heidi
    Reed, Carol R.
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (03) : 326 - 333
  • [32] Efficacy and Safety of Vilazodone in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
    Croft, Harry A.
    Pomara, Nunzio
    Gommoll, Carl
    Chen, Dalei
    Nunez, Rene
    Mathews, Maju
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2014, 75 (11) : E1291 - E1298
  • [33] Efficacy and Safety of Vilazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Trial
    Pomara, Nunzio
    Gommoll, Carl
    Chen, Dalei
    Nunez, Rene
    Mathews, Maju
    Croft, Harry A.
    [J]. NEUROPSYCHOPHARMACOLOGY, 2013, 38 : S378 - S379
  • [34] Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial
    Kato, Masaki
    Nakagome, Kazuyuki
    Baba, Takamichi
    Sonoyama, Takuhiro
    Okutsu, Daiki
    Yamanaka, Hideki
    Shimizu, Ryosuke
    Motomiya, Tomoko
    Inoue, Takeshi
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2023, 77 (09) : 497 - 509
  • [35] Efficacy of fructooligosaccharide versus placebo for treatment of acute diarrhea in children: A double-blind randomized clinical trial
    Suryanty, Reni
    Supriatmo
    Hasibuan, Berlian
    Sinuhaji, Atan Baas
    [J]. PAEDIATRICA INDONESIANA, 2005, 45 (3-4) : 65 - 68
  • [36] Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial
    Aida Khadivi
    Parnian Shobeiri
    Sara Momtazmaneh
    Farhaneh-Sadat Samsami
    Mohammadreza Shalbafan
    Elham Shirazi
    Shahin Akhondzadeh
    [J]. Psychopharmacology, 2022, 239 : 551 - 559
  • [37] Cilostazol as an adjunctive treatment in major depressive disorder: a pilot randomized, double-blind, and placebo-controlled clinical trial
    Khadivi, Aida
    Shobeiri, Parnian
    Momtazmaneh, Sara
    Samsami, Farhaneh-Sadat
    Shalbafan, Mohammadreza
    Shirazi, Elham
    Akhondzadeh, Shahin
    [J]. PSYCHOPHARMACOLOGY, 2022, 239 (02) : 551 - 559
  • [38] Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study
    Ou, Jian-Jun
    Xun, Guang-Lei
    Wu, Ren-Rong
    Li, Le-Hua
    Fang, Mao-Sheng
    Zhang, Hong-Geng
    Xie, Shi-Ping
    Shi, Jian-Guo
    Du, Bo
    Yuan, Xue-Qin
    Zhao, Jing-Ping
    [J]. PSYCHOPHARMACOLOGY, 2011, 213 (2-3) : 639 - 646
  • [39] Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study
    Jian-Jun Ou
    Guang-Lei Xun
    Ren-Rong Wu
    Le-Hua Li
    Mao-Sheng Fang
    Hong-Geng Zhang
    Shi-Ping Xie
    Jian-Guo Shi
    Bo Du
    Xue-Qin Yuan
    Jing-Ping Zhao
    [J]. Psychopharmacology, 2011, 213 : 639 - 646
  • [40] Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial
    Hoobehfekr, Saba
    Moghaddam, Hossein Sanjari
    Shalbafan, Mohammadreza
    Hashemi, Maryam Ghazizadeh
    Pirmoradi, Mohammad Mehdi
    Sakenian, Amirhossein
    Poopak, Amirhossein
    Kashefinejad, Shayan
    Yarahmadi, Masoomeh
    Akhondzadeh, Shahin
    [J]. PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (02) : 57 - 62